Brokers Issue Forecasts for BMRN FY2025 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRNFree Report) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of BioMarin Pharmaceutical in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer expects that the biotechnology company will post earnings of $3.09 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $90.00 target price on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.50 per share.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Free Report) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($0.23). BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. The firm had revenue of $746.00 million during the quarter, compared to the consensus estimate of $703.37 million. During the same quarter in the prior year, the firm posted $0.26 earnings per share. The business’s revenue for the quarter was up 28.4% compared to the same quarter last year.

BMRN has been the topic of a number of other reports. JPMorgan Chase & Co. reduced their price target on BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 30th. Wolfe Research assumed coverage on BioMarin Pharmaceutical in a research report on Friday, November 15th. They set an “outperform” rating and a $95.00 target price on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $80.00 price target on shares of BioMarin Pharmaceutical in a report on Wednesday, October 30th. Barclays cut their price objective on shares of BioMarin Pharmaceutical from $110.00 to $86.00 and set an “overweight” rating on the stock in a report on Friday, October 4th. Finally, Robert W. Baird lowered their target price on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. Seven analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $94.20.

Check Out Our Latest Stock Report on BMRN

BioMarin Pharmaceutical Trading Up 0.3 %

NASDAQ BMRN opened at $62.19 on Wednesday. The firm has a market cap of $11.85 billion, a PE ratio of 37.24, a price-to-earnings-growth ratio of 0.55 and a beta of 0.29. BioMarin Pharmaceutical has a 52 week low of $60.63 and a 52 week high of $94.85. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11. The company has a 50 day moving average price of $65.22 and a 200 day moving average price of $73.93.

Insider Activity

In related news, EVP Charles Greg Guyer sold 5,278 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the sale, the executive vice president now owns 68,909 shares in the company, valued at approximately $4,573,490.33. This trade represents a 7.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.85% of the company’s stock.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several hedge funds have recently modified their holdings of BMRN. Susquehanna Fundamental Investments LLC acquired a new position in BioMarin Pharmaceutical in the 2nd quarter worth about $5,627,000. Teachers Retirement System of The State of Kentucky increased its position in shares of BioMarin Pharmaceutical by 17.4% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 194,207 shares of the biotechnology company’s stock valued at $15,990,000 after buying an additional 28,837 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of BioMarin Pharmaceutical by 461.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company’s stock worth $40,205,000 after buying an additional 502,695 shares during the period. Wedmont Private Capital purchased a new position in shares of BioMarin Pharmaceutical during the 4th quarter valued at approximately $430,000. Finally, EULAV Asset Management lifted its position in shares of BioMarin Pharmaceutical by 12.9% during the 3rd quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company’s stock valued at $9,208,000 after buying an additional 15,000 shares in the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

About BioMarin Pharmaceutical

(Get Free Report)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Stories

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.